TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review): Review Decision - May 2008
Review of NICE Technology Appraisal Guidance No 91; paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for ovarian cancer (advanced) ? 2nd line
During consultation, the majority of comments received by the Institute agreed with the proposal, to defer the review of the guidance until November 2009. After consideration of all of the comments, the Institute's Guidance Executive have decided to proceed with the proposal.
12 May 2008
This page was last updated: 30 March 2010